$BNOEF $BNOX
If the PtSD trail hasn't failed I would be astound.
Looks like someone already knows the outcome of the trail.
When the SP decreases until readouts that's most likely a hint of a failure and a leak too (just look at SEEL).
Plus Bionomics and Bnc210 has has a history of trail failures (PTSD and SAD trails).
$BNOX $BNOEF
1K $BNOX Shares traded today (47K AVG).
In Australia 270K traded (1,5 Mio. AVG).
Seems like nobody wants to buy this 💩 I guess, or somebody already knows that the PTSD trail failed.
And that the study will fail just like the previous PTSD and SAD trails as it seems as BNC210 just isn't working.
$BNOEF
Upcoming Milestones / Activities
1. Release of broader dataset for BNC210 PREVAIL study in SAD expected 1H2023.
2. General Meeting of shareholders to be held virtually via an online platform, at 8:30am, Tuesday, 21 February 2023 (ACDT).
3. Topline data for BNC210 ATTUNE study in PTSD expected Mid-2023.
4. A copy of the full release, including a copy of the ASX Appendix 4C Cashflow Report can be found on the Company's website.
$BNOEF Activity Report
The Company also continued to closely manage its ongoing Phase 2b ATTUNE Study in PTSD including over-seeing the recurring Independent Safety Review Committee meetings and working with the Contract Research Organisation ("CRO") to maximize the ongoing study enrollment. As part of these efforts, the ATTUNE Study has been expanded to include seven sites in the United Kingdom and these sites have recently begun enrolling study participants.
Finally, with the additional financing activities during the quarter, the Company has sufficient cash runway to support its ongoing activities and upcoming milestones with runway to at least mid-2024.
$BNOEF
1. BNC210 for Treatment of Social Anxiety Disorder (SAD) Did Not Meet Primary Endpoint
2. Subjects with Confirmed SAD who Received BNC210 Exhibited Trends Toward Improvements Across Endpoints Compared to Placebo.
3. BNC210 Demonstrated Favourable Safety and Tolerability Profile Consistent with Prior Experience.
4. Company is Continuing Analysis of the Data and Evaluating Next Steps with Cash Runway into mid-2024.
$BNOEF
The Company is continuing analysis of the PREVAIL dataset and is assessing next steps for the development of BNC210 in SAD.
Payments for research and development expenditure during the Quarter increased to $6.32 million mainly relating to the Phase 2 ATTUNE PTSD and PREVAIL SAD Study expenditures. This represents an increase of 77.71% from the previous Quarter's payments of $3.50 million.
The Company's cash balance on 31 December 2022 was $30.70 million (30 September 2022: $31.43 million).
For the purpose of Listing Rule 4.7C.3, during the Quarter, the Executive Chairman was paid $207,000 for consulting fees and $8,000 for reimbursement of health benefit insurance, in accordance with the consulting agreement, and the other Directors were paid fees of $140,000.
$BNOEF $bnoax
Looks like BNC210 failed again!
Would be very surprised if the PTSD trail will not fail too.
https://www.globenewswire.com/news-release/2022/12/19/2575875/0/en/Bionomics-Reports-Topline-Results-in-PREVAIL-Phase-2-Study-of-BNC210-in-Social-Anxiety-Disorder.html
$BNOEF $BNOX
Anybody still here?
Do you think we'll get the SAD Ph2 Data in November like scheduled?
I think this trail is make or break for the company.
While good results might lift us back to .30 - .40 AUD.
Bad result would probably turn the lights off.
GLTA 🍀
